Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Mesenchymal Stem Cells for Spinal Cord Injury: Current Options, Limitations, and Future of Cell Therapy

Cofano F., Boido M., Monticelli M., Zenga F., Ducati A., Vercelli A.

Clinical Trial on Spinal Cord Injury, published in Int J Mol Sci (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2019)
Reported sample size
—
Source database
Europe PMC
PMID
31159345
PMCID
PMC6600381
DOI
10.3390/ijms20112698
Citations
290

Abstract (original English)

Spinal cord injury (SCI) constitutes an inestimable public health issue. The most crucial phase in the pathophysiological process of SCI concerns the well-known secondary injury, which is the uncontrolled and destructive cascade occurring later with aberrant molecular signaling, inflammation, vascular changes, and secondary cellular dysfunctions. The use of mesenchymal stem cells (MSCs) represents one of the most important and promising tested strategies. Their appeal, among the other sources and types of stem cells, increased because of their ease of isolation/preservation and their properties. Nevertheless, encouraging promise from preclinical studies was followed by weak and conflicting results in clinical trials. In this review, the therapeutic role of MSCs is discussed, together with their properties, application, limitations, and future perspectives.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansSpinal Cord InjuriesDisease Models, AnimalNerve Growth FactorsBiocompatible MaterialsCord Blood Stem Cell TransplantationMesenchymal Stem Cell TransplantationRegenerative Medicine

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research